More reads
- After FDA approval, drug makers often commit to follow-up studies. Few are new, a review finds. (STAT Plus)
- How Big Pharma suppresses biosimilars. (Wall Street Journal)
- Top biotech investor looking beyond the 'sexy' parts of healthcare as he places his next bets. (Business Insider)
- Krystal Biotech shares rise after skin drug gets expedited review from FDA. (MarketWatch)
No hay comentarios:
Publicar un comentario